Ad 293 cell line

Twenty human umbilical cords were collected from the Hsinchu Cathay General Hospital, approved by the Hospital Human Subjects Review Committee (approval numbers CT9672 and CGH-P101088). Human samples were de-identified prior to being used in this study. The experiments were carried out in accordance with the World Medical Association Declaration of Helsinki. Human umbilical vein ECs were isolated from human umbilical cords by collagenase perfusion as previously described (38 (link)) and grown in medium 199 (Gibco) supplemented with 20% fetal bovine serum (FBS, Gibco), 20% endothelial cell growth medium (Cell Applications), and 1% penicillin/streptomycin (P/S, Gibco). ECs between passages 2 and 4 were used in the experiments. The AD-293 cell line (Agilent Technologies) derived from the standard HEK293 with improved cell adherence and plaque formation properties was cultured in Dulbecco’s Modified Eagle Medium (Gibco) supplemented with 10% FBS and 1% P/S. Human monocytic cell line U937 (ATCC) was cultured in Roswell Park Memorial Institute 1640 (Gibco) supplemented with 10% FBS and 1% P/S.

Mouse lymphoma cell lines, RMA (H-2^b) and TAP-2-deficient RMA-S (H-2^b),^{19 (link)} were cultured in RPMI-1640 medium (Sigma-Aldrich, St. Louis, MO) with 10% FCS (Sigma-Aldrich) (R-10). The HHD gene-transfected cell lines, RMA-HHD and RMA-S-HHD, were previously described,^{15 (link)} and maintained in R-10 containing 500 μg/ml G418 (Nacalai Tesque, Kyoto, Japan). A human kidney cell line, 293 cell lines were obtained from the American Type Culture Collection (ATCC) (Rockville, MD). The Ad-293 cell line was provided with the AdEasy adenoviral vector system (Agilent Technologies, La Jolla, CA). 293 and Ad-293 cells were maintained in DMEM (Sigma-Aldrich) supplemented with 10% FCS (Sigma-Aldrich).